PRTA | Prothena Corporation plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	20.12 - 20.90
52 Week Range	18.69 - 56.04
Beta	0.44
Implied Volatility	62.29%
IV Rank	10.43%
Day's Volume	255,303
Average Volume	446,703
Shares Outstanding	53,780,300
Market Cap	1,093,353,499
Sector	Healthcare
Industry	Biotechnology
IPO Date	2012-12-18

Valuation
Profitability
Growth
Health
P/E Ratio	-21.63
Forward P/E Ratio	N/A
EPS	-0.94
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	173
Country	Ireland
Website	PRTA

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA's peers: SCPH, MIST, ONCY, MCRB, LIFE, ETNB, MDGL, PLRX, ACLX, STOK, VTYX, IMCR, PCVX, DICE, NUVL, CGEM, KNSA, VRDN

*Chart delayed

Analyzing fundamentals for PRTA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see PRTA Fundamentals page.

Watching at PRTA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PRTA Technicals page.